Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Historical Holders from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
KURA on Nasdaq
Shares outstanding
87,001,862
Price per share
$10.39
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
83,953,188
Total reported value
$743,091,012
% of total 13F portfolios
0%
Share change
+2,020,687
Value change
+$26,560,575
Number of holders
198
Price from insider filings
$10.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% +31% $76,791,609 +$24,465,506 8,677,018 +47% BVF PARTNERS L P/IL 30 Sep 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +39% $49,222,110 +$15,381,900 7,561,000 +45% SUVRETTA CAPITAL MANAGEMENT, LLC 31 Mar 2025
BlackRock, Inc. 7.8% -24% $41,202,116 -$10,448,902 6,329,050 -20% BlackRock, Inc. 31 Mar 2025
ARMISTICE CAPITAL, LLC 5.4% -28% $41,347,200 -$16,815,000 4,672,000 -29% Armistice Capital, LLC 30 Sep 2025
EcoR1 Capital, LLC 4.8% $23,520,000 4,200,000 EcoR1 Capital, LLC 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% $26,070,011 4,004,610 RA Capital Management, L.P. 31 Mar 2025
As of 30 Sep 2025, Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA) has 198 institutional shareholders filing 13F forms. They hold 83,953,188 shares. of 87,001,862 outstanding shares (96%) .

Top 25 institutional shareholders own 78% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 9,515,135 +0.47% 0% $84,208,945
BVF INC/IL 9.9% 8,617,162 +11% 3.1% $76,261,884
SUVRETTA CAPITAL MANAGEMENT, LLC 9.3% 8,116,000 0% 2.2% $71,826,600
VANGUARD GROUP INC 6.3% 5,468,522 +2.2% 0% $48,396,420
ARMISTICE CAPITAL, LLC 5.4% 4,672,000 -25% 1.3% $41,347,200
STATE STREET CORP 3.8% 3,343,131 +10% 0% $29,586,709
Prosight Management, LP 3.2% 2,758,516 -13% 5.9% $24,412,867
GOLDMAN SACHS GROUP INC 3% 2,614,726 +180% 0% $23,140,325
AQR CAPITAL MANAGEMENT LLC 2.6% 2,242,192 +138% 0.01% $19,843,399
JACOBS LEVY EQUITY MANAGEMENT, INC 2.6% 2,224,590 +102% 0.08% $19,687,622
MILLENNIUM MANAGEMENT LLC 2.4% 2,093,702 -20% 0.01% $18,529,263
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,047,926 +1.7% 0% $18,127,511
MORGAN STANLEY 2.1% 1,813,064 -8.6% 0% $16,045,621
Qube Research & Technologies Ltd 2% 1,712,716 -10% 0.02% $15,157,537
ALETHEA CAPITAL MANAGEMENT, LLC 1.6% 1,388,794 +46% 7.9% $12,290,827
Assenagon Asset Management S.A. 1.5% 1,265,030 +38% 0.02% $11,195,516
DIMENSIONAL FUND ADVISORS LP 1.3% 1,139,365 -8.3% 0% $10,083,861
ACADIAN ASSET MANAGEMENT LLC 1.2% 1,060,829 +22% 0.02% $9,387,000
ALGERT GLOBAL LLC 1.2% 1,011,945 -5.4% 0.15% $8,956,000
EcoR1 Capital, LLC 1% 872,500 -79% 0.37% $7,721,625
RENAISSANCE TECHNOLOGIES LLC 0.99% 865,310 -18% 0.01% $7,657,994
CITADEL ADVISORS LLC 0.93% 808,818 +122% 0.01% $7,158,040
NORTHERN TRUST CORP 0.87% 753,600 +8.6% 0% $6,669,361
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.82% 711,896 +1.8% 0% $6,300,280
AMERICAN CENTURY COMPANIES INC 0.77% 669,046 +187% 0% $5,921,057

Institutional Holders of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 1,437,394 $14,817,611 -$30,746 $10.39 8
2025 Q3 83,953,188 $743,091,012 +$26,560,575 $8.85 198
2025 Q2 82,161,271 $474,076,451 +$3,886,077 $5.77 180
2025 Q1 80,481,583 $531,240,145 -$1,742,391 $6.60 183
2024 Q4 78,800,102 $686,302,860 -$217,671,932 $8.71 184
2024 Q3 82,360,607 $1,606,956,703 +$4,044,498 $19.54 178
2024 Q2 80,489,635 $1,657,260,003 -$4,649,743 $20.59 173
2024 Q1 80,704,151 $1,721,386,349 +$47,334,824 $21.33 162
2023 Q4 78,750,714 $1,132,429,796 +$48,405,539 $14.38 138
2023 Q3 75,320,060 $686,894,075 -$2,210,555 $9.12 131
2023 Q2 75,143,461 $795,074,726 +$20,118,060 $10.58 147
2023 Q1 72,452,228 $885,285,317 +$27,367,401 $12.23 140
2022 Q4 70,164,281 $870,596,716 -$25,367,145 $12.41 139
2022 Q3 71,584,721 $977,803,865 -$10,119,008 $13.66 144
2022 Q2 68,658,415 $1,258,498,156 +$54,233,601 $18.33 142
2022 Q1 65,777,551 $1,057,605,942 +$39,092,796 $16.08 142
2021 Q4 64,108,565 $897,784,334 -$107,625,141 $14.00 143
2021 Q3 66,738,474 $1,250,027,023 -$22,664,956 $18.73 149
2021 Q2 67,619,494 $1,409,907,095 -$33,759,405 $20.85 163
2021 Q1 68,584,982 $1,942,401,972 +$106,818,236 $28.27 162
2020 Q4 65,052,975 $2,124,984,562 +$353,968,960 $32.66 192
2020 Q3 53,818,393 $1,648,931,451 +$50,643,099 $30.64 160
2020 Q2 52,442,231 $855,540,393 +$213,208,168 $16.30 129
2020 Q1 39,802,987 $394,470,751 +$5,045,270 $9.95 113
2019 Q4 38,979,999 $536,059,777 -$17,580,300 $13.75 125
2019 Q3 40,174,979 $609,372,943 +$18,475,235 $15.17 114
2019 Q2 38,684,419 $761,718,678 +$133,021,751 $19.69 121
2019 Q1 32,044,753 $531,121,734 -$3,584,064 $16.59 100
2018 Q4 32,415,330 $454,789,379 -$2,761,213 $14.04 95
2018 Q3 30,235,029 $529,138,565 +$7,587,244 $17.50 112
2018 Q2 29,714,074 $540,689,653 +$112,569,821 $18.20 108
2018 Q1 23,570,284 $441,929,475 +$77,404,250 $18.75 98
2017 Q4 19,535,236 $298,877,651 +$581,471 $15.30 73
2017 Q3 19,416,540 $290,234,810 +$128,771,717 $14.95 64
2017 Q2 10,813,395 $100,551,904 +$4,771,007 $9.30 42
2017 Q1 10,310,503 $90,718,000 +$4,182,413 $8.80 34
2016 Q4 9,877,148 $58,241,000 +$736,496 $5.90 29
2016 Q3 9,748,853 $60,931,000 +$2,850,289 $6.25 25
2016 Q2 9,319,042 $25,248,000 -$3,677,975 $2.71 25
2016 Q1 10,225,954 $41,413,000 -$249,669 $4.05 20
2015 Q4 10,246,869 $86,073,000 +$80,324,000 $8.40 14